Trial Profile
Expanded Access Multicenter Study of Lucanix (Belagenpumatucel-L) in Advanced Non-small Cell Lung Cancer.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Jun 2011
Price :
$35
*
At a glance
- Drugs Belagenpumatucel-L (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 28 Feb 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 27 Jan 2011 New trial record